ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Noninvasive prediction of glypican-3 expression and recurrence-free survival in hepatocellular carcinoma using contrast-enhanced ultrasound.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Prediction of Glypican-3 Expression in Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasound Radiomics.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlypican-3 (GPC-3) is a promising biomarker and therapeutic target in hepatocellular carcinoma (HCC), yet its noninvasive preoperative assessment remains challenging. This study developed and validated a nomogram model integrating contrast-enhanced ultrasound (CEUS) features with clinical variables to predict GPC-3 expression and assess its prognostic significance for recurrence-free survival (RFS).
methodsA retrospective analysis of 316 HCC patients who underwent preoperative CEUS was performed. Predictive CEUS features and clinical variables were identified using least absolute shrinkage and selection operator regression and multivariable logistic regression. The nomogram was constructed and validated in training and validation cohorts, with performance assessed by receiver operating characteristic curve, calibration curves, and decision curve analysis. Kaplan-Meier and Cox regression analyses were used to assess the association between GPC-3 expression, nomogram scores, and RFS.
resultsThe median age of the patients was 59 years (IQR, 52–67 years), with a predominance of male patients (267/316, 84.49%). Four predictors of GPC-3 expression were identified: alpha-fetoprotein, feeding artery, hyper-enhanced rim in the arterial phase, and necrosis. The nomogram achieved area under the curve values of 0.90 (95% CI: 0.86, 0.94) in the training cohort and 0.88 (95% CI: 0.80, 0.94) in the validation cohort. The positive predictive value and negative predictive value were 97.14% (95% CI: 94.38, 99.90) and 54.32% (95% CI: 43.47, 65.17) in the training cohort, and 96.77% (95% CI: 91.80, 99.99) and 45.46% (95% CI: 28.12, 62.08) in the validation cohort, respectively. Calibration plots and decision curve analysis confirmed its clinical utility. GPC-3 expression was identified as an independent prognostic factor for RFS (hazard ratio: 3.56; 95% CI: 2.18, 5.83), and patients with high nomogram scores had significantly shorter RFS (P < 0.001).
conclusionsThis CEUS-based nomogram provides an accurate, noninvasive method for predicting GPC-3 expression and RFS in HCC patients, serving as a valuable tool for personalized treatment strategies and optimizing GPC-3-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.